ADAM17 and hepatocellular carcinoma: In the early stages of HCC, HNF4A could inhibit cell proliferation of HCC through the miR-122-adam17 pathway (Yang et al., 2020), and downregulation of HNF4A could lead to loss of hepatocyte characteristics (Ramesh and Ganesan, 2016).